Company / Return on Assets (ROA)
Jade Biosciences, Inc. Return on Assets (ROA) History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-86.7%
FY2024
5-year range
-203.8% / -13.1%
FY2020-FY2024
Trend
-46.2%
vs FY2023
Sector context
#202 of 213
Health Care
What the data says
Among 213 Health Care companies, Jade Biosciences, Inc. is in the bottom 5% for return on assets (roa). Return on Assets (ROA) has declined for 3 consecutive years, from -13.1% in FY2021 to -86.7% in FY2024.
Based on SEC 10-K filings.
-86.7% in FY2024 with a 3-year CAGR of -73.6%.
Declined from -38.1% to -86.7% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -73.6pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 213This company -86.7% Sector average -24.1%
▼
-258.9% below sector average
Key checks
Key Insights
- Jade Biosciences, Inc.'s return on assets (roa) has declined for 3 consecutive years.
- In FY2024, return on assets (roa) decreased 46.2% year-over-year.
- Currently 62.5pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.03 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -86.7% | -46.2% |
| FY2023 | -59.3% | -55.7% |
| FY2022 | -38.1% | -190.8% |
| FY2021 | -13.1% | +93.6% |
| FY2020 | -203.8% | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026